Cargando…
The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers
Non-Hodgkin lymphoma (NHL) and leukemia are among the most common cancers worldwide. While the treatment of NHL/leukemia of B-cell origin has much progressed with the introduction of targeted therapies, few treatment standards have been established for T-NHL/leukemia. As presentation in both B- and...
Autores principales: | Angelova, Assia L., Witzens-Harig, Mathias, Galabov, Angel S., Rommelaere, Jean |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427078/ https://www.ncbi.nlm.nih.gov/pubmed/28553616 http://dx.doi.org/10.3389/fonc.2017.00093 |
Ejemplares similares
-
Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1
por: Moehler, Markus, et al.
Publicado: (2014) -
Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients
por: Angelova, Assia L., et al.
Publicado: (2015) -
Oncolytic parvoviruses: from basic virology to clinical applications
por: Marchini, Antonio, et al.
Publicado: (2015) -
Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity
por: Angelova, Assia L., et al.
Publicado: (2017) -
Parvovirus-Based Combinatorial Immunotherapy: A Reinforced Therapeutic Strategy against Poor-Prognosis Solid Cancers
por: Angelova, Assia, et al.
Publicado: (2021)